TABLE 4.
Test of significance in relapse rates among different groups
| Groups compared | χ2 or c valuea | P value | Table no. |
|---|---|---|---|
| Primaquine vs bulaquine (1-yr follow-up) | χ2 = 0.44 (df = 1) | 0.7 > P > 0.5 | 1 |
| Combined treatment vs placebo (1-yr follow-up) | χ2 = 9.66∗ (df = 1) | 0.01 > P > 0.001 | 1 |
| Short term in primaquine vs bulaquine (within 6 mo) | χ2 = 0.05 (df = 1) | 0.9 > P > 0.8 | 2 |
| Long term in primaquine vs bulaquine (within 7–12 mo) | χ2 = 1.39 (df = 1) | 0.3 > P > 0.2 | 2 |
| Short term in combined vs placebo (within 6 mo) | χ2 = 0.83 (df = 1) | 0.4 > P > 0.3 | 2 |
| Long term in combined vs placebo (within 7–12 mo) | χ2 = 9.49 (df = 1) | 0.01 > P > 0.001 | 2 |
| Short and long in placebo, first half yr vs second half yr | χ2 = 15.40∗ (df = 2) | P < 0.001 | 3 |
| Short and long in bulaquine vs primaquine, first half yr | χ2 = 4.82 (df = 2) | 0.1 > P > 0.05 | 3 |
| Short and long in bulaquine vs primaquine, second half yr | χ2 = 0.83 (df = 2) | 0.7 > P > 0.6 | 3 |
| Short and long in combined vs placebo, first half yr | χ2 = 0.40 (df = 2) | 0.9 > P > 0.8 | 3 |
| Short and long in combined vs placebo, second half yr | χ2 = 12.02∗ (df = 2) | 0.01 > P > 0.001 | 3 |
| Short term in combined vs placebo, first half yr | c = 0.57 | 0.60 > P > 0.50 | 3 |
| Short term in combined vs placebo, second half yr | c = 0.66 | 0.50 > P > 0.40 | 3 |
| Short term in combined, first half yr vs second half yr | c = 2.94∗ | 0.01 > P > 0.001 | 3 |
| Long term in combined vs placebo, first half yr | c = 0.17 | 0.9 > P > 0.8 | 3 |
| Long term in combined vs placebo, second half yr | c = 3.02∗ | 0.01 > P > 0.001 | 3 |
| Long term in combined, first half yr vs second half yr | c = 4.11∗ | P < 0.001 | 3 |
a
∗, significant; df, degrees of freedom.